Hypertension Treatment Algorithm
HYPERTENSION TREATMENT ALGORITHM | |||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Adults ≥18yrs with hypertension | |||||||||||||||||||||||||
▼ | |||||||||||||||||||||||||
Implement lifestyle modifications (continue throughout management) | |||||||||||||||||||||||||
▼ | |||||||||||||||||||||||||
Set blood pressure (BP) goal and initiate BP-lowering medication based on age, diabetes, and chronic kidney disease (CKD) | |||||||||||||||||||||||||
General population (no diabetes or CKD) |
Diabetes or CKD present | ||||||||||||||||||||||||
Age ≥60yrs | Age <60yrs |
• All ages • With diabetes • No CKD |
• All ages • CKD present w or w/o diabetes |
||||||||||||||||||||||
BP Goal <150/90mmHg | BP Goal <140/90mmHg | BP Goal <140/90mmHg | BP Goal <140/90mmHg | ||||||||||||||||||||||
Non-black | ▼ | ▼ | Black | ▼ | All races | ||||||||||||||||||||
Initiate thiazide-type diuretic, ACEI, ARB, or CCB, alone or in combinationa | Initiate thiazide-type diuretic or CCB, alone or in combination | Initiate ACEI or ARB, alone or in combination with other classa | |||||||||||||||||||||||
Select drug treatment titration strategy:
A. Maximize first medication before adding second OR B. Add second medication class before maximizing first medication OR C. Start with two medication classes separately or as a fixed-dose combination |
|||||||||||||||||||||||||
At goal?b | Yes | ||||||||||||||||||||||||
No | ▼ | ||||||||||||||||||||||||
• Reinforce medication and lifestyle adherence • Strategy A or B: Add and titrate thiazide-type diuretic, ACEI, ARB, or CCB (use class not previously selected)a • Strategy C: Maximize dose of initial regimen |
|||||||||||||||||||||||||
At goal? | Yes | ||||||||||||||||||||||||
No | ▼ | ||||||||||||||||||||||||
• Reinforce medication and lifestyle adherence • Add and titrate thiazide-type diuretic, ACEI, ARB, or CCB (use class not previously selected)a |
|||||||||||||||||||||||||
At goal? | Yes | ||||||||||||||||||||||||
No | ▼ | ||||||||||||||||||||||||
► |
• Reinforce medication and lifestyle adherence • Add additional class (eg, β-blocker, aldosterone antagonist, or others not previously selected) and/or refer to hypertension specialist |
||||||||||||||||||||||||
▼ | |||||||||||||||||||||||||
No | At goal? | Yes | ► | Continue current therapy and monitoringc | |||||||||||||||||||||
FIRST LINE THERAPY FOR COMPELLING INDICATIONS | |||||||||||||||||||||||||
Compelling indication | First-line Therapy | ||||||||||||||||||||||||
Heart failure |
ACEI, ARB, angiotensin receptor-neprilysin inhibitor, mineralocorticoid receptor antagonist, diuretic, BB (carvedilol, metoprolol succinate, bisoprolol) |
||||||||||||||||||||||||
Post myocardial infarction |
BBd (carvedilol, metoprolol, nadolol, bisoprolol, propranolol, timolol), ACEI, ARB |
||||||||||||||||||||||||
Diabetes |
Thiazide diuretic, ACEI, ARB, CCB |
||||||||||||||||||||||||
Chronic kidney disease (CKD) |
ACEI, ARB |
||||||||||||||||||||||||
Secondary stroke prevention |
Thiazide diuretic, ACEI, ARB |
||||||||||||||||||||||||
LIFESTYLE MODIFICATIONS | |||||||||||||||||||||||||
Modification | Recommendation | Approximate SBP reduction | |||||||||||||||||||||||
Weight loss |
Aim for at least a 1kg reduction in body weight; best goal is ideal body weight |
1mmHg/kg of weight loss |
|||||||||||||||||||||||
DASH diet (Dietary Approaches to Stop Hypertension) |
Adopt a diet rich in fruits, vegetables, whole grains, and low-fat dairy products with reduced content of saturated and total fat |
3−11mmHg |
|||||||||||||||||||||||
Sodium reduction |
Reduce dietary sodium intake by at least 1000mg/day; optimal goal is <1500mg/day |
2−6mmHg |
|||||||||||||||||||||||
Potassium supplementation |
Increase dietary potassium intake to 3500−5000mg/day. Four to five servings of fruits and vegetables will usually provide 1500−>3000mg of potassium |
2−5mmHg |
|||||||||||||||||||||||
Physical activity |
Increase physical activity: |
|
|||||||||||||||||||||||
|
• Aerobic exercise: 90−150mins/wk |
2−8mmHg |
|||||||||||||||||||||||
|
• Dynamic resistance: 90−150mins/wk |
2−4mmHg |
|||||||||||||||||||||||
|
• Isometric resistance: 3 sessions/wk for 8−10wks |
4−5mmHg |
|||||||||||||||||||||||
Reduced alcohol consumption |
Limit to no more than 2 drinks/day in men and 1 drink/day in women (1 drink = 12oz beer, 5oz wine, 1.5oz distilled spirit) |
3−4mmHg |
|||||||||||||||||||||||
Tobacco Cessation |
Provide behavioral interventions. May need to consider pharmacotherapy for cessation |
— |
|||||||||||||||||||||||
STRATEGIES TO IMPROVE TREATMENT ADHERENCE | |||||||||||||||||||||||||
• Clinician empathy increases patient trust, motivation and adherence to therapy • Clinicians should consider patients’ cultural beliefs and individual attitudes in formulating a treatment plan • Simplifying medication regimens: — Dosing to once daily rather than multiple times per day may improve adherence — Use of fixed-dose combination agents rather than individual drug components |
|||||||||||||||||||||||||
NOTES | |||||||||||||||||||||||||
Key: CVD = cardiovascular disease; ARB = angiotensin II receptor blocker; ACEI = angiotensin converting enzyme inhibitor; BB = beta blocker; CCB = calcium channel blocker a Avoid combination of ACEIs and ARBs. b Wait 1 month before titrating. c If BP goal not maintained, re-enter the algorithm where appropriate; individualize. d Avoid atenolol or BB with intrinsic sympathomimetic activity. |
|||||||||||||||||||||||||
REFERENCES | |||||||||||||||||||||||||
James PA, Oparil S, et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults. Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507-520. doi:10.1001/jama.2013.284427. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2017. doi: 10.1016/j.jacc.2017.11.006 (Rev. 3/2018) |